Search

Your search keyword '"Biotechnology industry -- Licensing agreements"' showing total 534 results
Start Over Descriptor "Biotechnology industry -- Licensing agreements" Search Limiters Available in Library Collection
534 results on '"Biotechnology industry -- Licensing agreements"'

1. An Interview with Tony Talalay, Co-Founder and CEO, Brassica Protection Products LLC

Author

Baker, Sheldon

Subjects
Brassica Protection Products L.L.C. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Dietary supplements -- Licensing agreements, Functional foods -- Licensing agreements, Company licensing agreement, Business, Pharmaceuticals and cosmetics industries, Food and beverage industries
Abstract

Tony Talalay is the CEO, co-founder, and member of the board of managers of Brassica Protection Products. Talalay completed strategic licensing agreements with Johns Hopkins University and raised initial and [...]

Published
2023

2. Provision For Notice Of Intent To Sole Source Meridian Bioscience Inc To Provide Curian Analyzer (610190) And Curian Hpsa Assay (760130)

Subjects
Meridian Bioscience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Analytical instruments -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Special Notice (Original): Notice of intent to sole source meridian bioscience inc. to provide curian analyzer (610190) and curian hpsa assay (760130). The medical readiness contracting office, west, fort hood, [...]

Published
2023

4. Arrowhead Gets $70M in Payments: Pasadena firm got money from pharma giants.

Author

Fine, Howard

Subjects
Biotechnology industry -- Licensing agreements, Liver, Drug approval, Pharmaceutical industry -- Licensing agreements, Arrowhead Pharmaceuticals Inc. -- Licensing agreements, Takeda Pharmaceutical Company Ltd. -- Licensing agreements, Amgen Inc. -- Licensing agreements, Johnson & Johnson -- Licensing agreements, Company licensing agreement
Abstract

Pasadena-based Arrowhead Pharmaceuticals Inc. has pursued a strategy of reaching massive licensing deals with major pharmaceutical companies to take over late-stage clinical trials and seek government approvals for drugs Arrowhead [...]

Published
2023

5. United States : Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers

Subjects
Gene expression, Genes, Biotechnology, Biotechnology industry -- Licensing agreements, Cancer -- Genetic aspects, Multiple myeloma, Company licensing agreement, Business, international
Abstract

-- Agreement Provides Kite with Additional Expertise in Synthetic Biology Space for Oncology -- Kite, a Gilead Company and Refuge Biotechnologies, Inc. (Refuge), announced that Kite has entered into an [...]

Published
2022

6. United Kingdom : AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19

Subjects
AstraZeneca PLC -- Licensing agreements, Biotechnology, Biotechnology industry -- Licensing agreements, Immunotherapy, Vaccines -- Licensing agreements, Monoclonal antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19. Under [...]

Published
2022

7. MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Subjects
MaxCyte Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Killer cells, Cancer -- Care and treatment -- Genetic aspects, Biological products -- Health aspects, Biomedical engineering, Company licensing agreement, Biotechnology industry, Health, Science and technology
Abstract

2023 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling [...]

Published
2023

8. United States : Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

Subjects
Exelixis Inc. -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Antibodies, Company licensing agreement, Business, international
Abstract

Exelixis, Inc. and Iconic Therapeutics, Inc. (Iconic) announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation [...]

Published
2022

9. Sweden : Alligator Bioscience enters into an oncology research collaboration and licensing agreement with Orion Corporation

Subjects
Alligator Bioscience -- Licensing agreements, Orion Corp. -- Licensing agreements, Industrial equipment and supplies industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology, Viral antibodies, Biotechnology industry -- Licensing agreements, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Alligator Bioscience announces that the company has entered into a research collaboration and licensing agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and jointly develop [...]

Published
2021

12. United States : Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Subjects
Advaxis Inc. -- Licensing agreements -- Finance, Biotechnology industry -- Licensing agreements, Company financing, Company licensing agreement, Business, international
Abstract

Advaxis, Inc. a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the second milestone payment related to its licensing [...]

Published
2021

13. Unique and hot topics in biotechnology licensing.

Author

Smith, Steven P.

Subjects
Patent licenses -- Laws, regulations and rules, Biotechnology industry -- Licensing agreements, Government regulation, Company licensing agreement
Abstract

The biotechnology field can be both dynamic and controversial. As a result, licensing biotechnology often requires unique treatment and constant reexamination, refocus and revision. Due to the unique requirements of [...]

Published
2008

15. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan IMMU-132, a Promising Late-Stage ADC for Solid Tumors

Subjects
Immunomedics Inc. -- Licensing agreements, Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Women -- Health aspects, Medical research, Medicine, Experimental, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Health, Women's issues/gender studies
Abstract

2017 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, announced a development and license [...]

Published
2017

16. Deals Pay Off at Arrowhead, Xencor: Companies earn payouts from licensing agreements.

Author

Fine, Howard

Subjects
Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Drug approval, Pharmaceutical industry -- Licensing agreements, Arrowhead Pharmaceuticals Inc. -- Licensing agreements, Amgen Inc. -- Licensing agreements, Xencor Inc. -- Licensing agreements, United States. Food and Drug Administration, Company licensing agreement
Abstract

Two San Gabriel Valley biopharmaceutical companies recently announced that they had received substantial milestone payments from licensing and development deals with pharmaceutical giants. On July 29, Pasadena-based Arrowhead Pharmaceuticals Inc. [...]

Published
2020

18. Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs

Subjects
MaxCyte Inc. -- Licensing agreements, T cells, Biotechnology industry -- Licensing agreements, Non-Hodgkin's lymphomas, Cancer -- Care and treatment -- Genetic aspects, Biological products -- Health aspects, Biomedical engineering, Company licensing agreement, Biotechnology industry, Health, Science and technology
Abstract

2021 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, [...]

Published
2021

19. United States : Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Seattle Genetics, Inc. and BeiGene, Ltd. announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary [...]

Published
2019

20. Biotechnology and pharmaceutical licensing.

Author

Linek, Ernest V.

Subjects
Biotechnology industry -- Licensing agreements, Patent infringement -- Laws, regulations and rules, Pharmaceutical industry -- Licensing agreements, Government regulation, Company licensing agreement, Drug Price Competition and Patent Term Restoration Act of 1984
Abstract

This column is intended to provide suggestions and case commentary that may assist the reader in dealing with licensing issues in technological areas where the Federal Food and Drug Administration [...]

Published
2008

21. Not invented here

Author

Ready, Tinker

Subjects
Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Merck & Company Inc. -- Licensing agreements
Published
2007

22. Ripe for the picking: Little biotech firms are catching the eye of Big Pharma. Juicy stocks?

Author

Alpert, Bill

Subjects
Pharmaceutical industry -- Licensing agreements, Biotechnology industry -- Research, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Only a small number of biotechnology firms have clinical test results to show a prospective bidder and such validated products are commanding high prices in the new license deals and acquisitions. In picking possible beneficiaries, firms with new treatments for the toughest medical problems, like cancer are highlighted.

Published
2004

23. Allenex granted right to market and sell three new products under extended agreement with Conexio

Subjects
Computer services industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Computer services industry, Company licensing agreement, Business, Computers and office automation industries
Abstract

WORLDWIDE COMPUTER PRODUCTS NEWS-June 16, 2014-Allenex granted right to market and sell three new products under extended agreement with Conexio (C)1995-2014 M2 COMMUNICATIONS http://www.m2.com Allenex AB (STO:ALNX), a Swedish company [...]

Published
2014

24. United States : Pieris Pharmaceuticals and Seattle Genetics Announce Multi-program Immuno-oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, Business, international
Abstract

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc., a global biotechnology company [...]

Published
2018

25. Mighty mice: the perils of patenting genes

Author

Allen, Arthur

Subjects
Mice as laboratory animals -- Research, Biotechnology industry -- Licensing agreements, Licensing agreements -- Economic aspects, E.I. du Pont de Nemours and Co. -- Licensing agreements -- 00302599
Published
1998

26. SANGAMO'S FULL PLATE OF DEALS

Author

Marcial, Gene

Subjects
Company licensing agreement, Company securities, Roche Holding Ltd. -- Licensing agreements, Sangamo BioSciences Inc. -- Licensing agreements, Sangamo BioSciences Inc. -- Securities, Sangamo BioSciences Inc. -- Alliances and partnerships, Pharmaceutical industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Biotechnology industry -- Securities, Biotechnology industry -- Alliances and partnerships
Published
2008

27. Cerenis to get $53.5M in VC; Biotech firm's deal is largest in state history

Author

Henderson, Tom

Subjects
Biotechnology industry -- Finance, Biotechnology industry -- Licensing agreements, Venture capital companies -- Investments, Company financing, Company licensing agreement, Company investment, Business, Business, regional
Abstract

Ann Arbor-based biotech company Cerenis Therapeutics Inc. will announce today at the American Heart Association's scientific conference in Chicago that it has agreed to terms on what is probably the [...]

Published
2006

28. Apoplexy: Renovis Takes Aim

Author

Marcial, Gene G.

Subjects
Company licensing agreement, Company financing, Company securities, Pfizer Inc. -- Licensing agreements, Renovis Inc. -- Licensing agreements, Renovis Inc. -- Finance, Renovis Inc. -- Securities, AstraZeneca PLC -- Licensing agreements, Biotechnology industry -- Finance, Biotechnology industry -- Licensing agreements, Biotechnology industry -- Securities, Pharmaceutical industry -- Licensing agreements
Published
2006

29. Crop Tech

Author

Burchett, Andrew

Subjects
United States. National Science Foundation -- Finance, Dow AgroSciences L.L.C. -- Licensing agreements, Sangamo BioSciences Inc. -- Licensing agreements, Soybean -- Genetic aspects, Soybean -- Research, Agricultural chemicals industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Genetically modified crops -- Research, Company financing, Company licensing agreement, Agricultural industry, Business, Purdue University -- Government finance
Abstract

Soybean Genome in the Limelight Corn and rice genome mapping projects have had their share of fanfare recently, but now the soybean genome is stepping into the spotlight. The National [...]

Published
2005

30. Three party agreement = cancer biomarker research

Subjects
University College London -- Licensing agreements, Company licensing agreement, Biotechnology industry -- Licensing agreements, Universities and colleges -- Licensing agreements -- United States -- United Kingdom, Ciphergen Biosystems Inc. -- Licensing agreements
Abstract

Ciphergen Biosystems has signed a research and license agreement with University College of London and UCL BioMedica Plc. to further ongoing research in ovarian cancer. Ciphergen and its UCL collaborators [...]

Published
2005

31. Business Diary

Subjects
FEV Engine Technology Inc. -- Buildings and facilities, Nippon Chemiphar Company Ltd. -- Licensing agreements, Velcura Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Industrial equipment and supplies industry -- Buildings and facilities, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, Business, regional
Abstract

ACQUISITIONS The Hayman Co., Troy, has acquired the Triad office property in Greenwood Village, Colo. Hayman plans about $2 million in renovations to the 411,000-square-foot property. CALL FOR NOMINATIONS The [...]

Published
2005

32. What Other Biotechs See in Bioenvision

Author

Marcial, Gene G.

Subjects
Company licensing agreement, Company securities, Bioenvision Inc. -- Securities, Bioenvision Inc. -- Product development, Bioenvision Inc. -- Licensing agreements, Genzyme Corp. -- Licensing agreements, Clofarabine (Medication) -- Licensing, certification and accreditation, Biotechnology industry -- Securities, Biotechnology industry -- Product development, Biotechnology industry -- Licensing agreements
Published
2005

33. Biogen Idec + Immunogen = anticancer antibodies

Subjects
Company licensing agreement, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, ImmunoGen Inc. -- Licensing agreements, Biogen Idec Inc. -- Licensing agreements
Abstract

Biogen Idec will use Immunogen's tumor-activated prodrug (TAP) technology with antibodies to an undisclosed tumor cell target. Biogen Idec will pay Immunogen $1 million upfront, up to $42 million in [...]

Published
2004

34. Calpyte + Bio-Rad = global HIV testing

Subjects
Bio-Rad Laboratories Inc. -- Licensing agreements, Chemical industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Pesticides industry -- Licensing agreements, Herbicides -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

Calpyte Biomedical licensed patents from Bio-Rad Laboratories that will allow Calpyte's rapid tests to diagnose HIV-2. Bio-Rad is the exclusive licensee of Institut [...]

Published
2004

35. Agrisoma + Dow AgroSciences = plant-based medicines for animals

Subjects
Agrisoma Biosciences Inc. -- Licensing agreements, Dow AgroSciences L.L.C. -- Technology application, Dow AgroSciences L.L.C. -- Licensing agreements, Biotechnology industry -- Technology application, Biotechnology industry -- Licensing agreements, Agricultural chemicals industry -- Licensing agreements, Company licensing agreement, Technology application, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

Agrisoma and Dow AgroSciences will use Agrisoma's ACE gene delivery and expression technology to research, develop, and commercialize animal health products. According to Agrisoma, this is the first commercial use [...]

Published
2004

36. Cambrex Bioproducts + Epoch Biosciences = improving microbial detection

Subjects
Epoch Biosciences Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

Cambrex Bioproducts licensed Epoch Biosciences' MGB Eclipse Probe System technology for its rapid microbial detection products and services. Cambrex will deliver an upfront payment to Epoch, buy MGB Eclipse probes [...]

Published
2004

37. Compound Therapeutics + Abbott Laboratories = selecting new antibody leads

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Licensing agreements, Compound Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Microbiological research -- Intellectual property, Biotechnology industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

Compound Therapeutics licensed its PROfusion technology and certain antibody libraries to Abbott Laboratories for drug discovery. The technology allows selection and rapid optimization of high-affinity antibodies and other binding [...]

Published
2004

38. Avoiding the train wreck: get the information you need while building a long-term relationship

Author

Slowinski, Gene and Watson, Dan

Subjects
Regulatory compliance -- Usage, Pharmaceutical industry -- Alliances and partnerships, Biotechnology industry -- Licensing agreements, Biotechnology industry -- Alliances and partnerships, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

When biotechnology CEOs get together, the conversation quickly turns to 'working with Big Pharma.' Few topics are discussed as passionately as surviving the due diligence process. Due diligence occurs when [...]

Published
2004

39. Private industry's most eligible: mining for licensing gold? Look for new prospects outside the US borders

Author

Lachman, Ranan

Subjects
Chief executive officers -- Beliefs, opinions and attitudes, Chief executive officers -- Surveys, Pharmaceutical industry -- Licensing agreements, Pharmaceutical industry -- Research, Biotechnology industry -- Licensing agreements, Biotechnology industry -- Research, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

In a recent survey of 261 CEOs and licensing executives of biotech companies, 84 percent acknowledged that they face one or more of the following challenges: * The ability to [...]

Published
2004

40. MorphoSys obtains Crucell cell line

Subjects
MorphoSys AG -- Licensing agreements, Crucell N.V. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

MorphoSys announced a non-exclusive licensing agreement with the Dutch biotechnology company Crucell and its allied contract manufacturer DSM Biologics. MorphoSys plans to use Crucell's fully human PER.C6 cell line for [...]

Published
2004

41. FILL 'ER UP -- WITH STRAW AND YEAST

Author

Arndt, Michael and Arndt, Catherine

Subjects
Company licensing agreement, Iogen Corp. -- Licensing agreements, Iogen Corp. -- Product development, Purdue University -- Licensing agreements, Purdue University -- Product development, Biotechnology industry -- Licensing agreements, Biotechnology industry -- Product development, Yeast fungi -- Properties, Yeast fungi -- Usage, Straw -- Usage, Alcohol, Denatured -- Production processes, Alcohol -- Production processes
Published
2004

42. Xcellsyz + Boehringer Ingelheim = ex-cell-ent cells

Subjects
Xcellsyz -- Licensing agreements, Boehringer Ingelheim GmbH -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

UK-based Xcellsyz will license its conditionally immortalized, human skeletal muscle cell lines to the German pharmaceutical company Boehringer Ingelheim for evaluation and drug discovery [...]

Published
2004

43. Deals, deals, deals. (In the News)

Author

de Myer, Desiree

Subjects
Roche Holding AG -- Licensing agreements, Roche Holding AG -- Contracts, Maxygen Inc. -- Contracts, Maxygen Inc. -- Licensing agreements, Pharmaceutical industry -- Contracts, Pharmaceutical industry -- Licensing agreements, Biotechnology industry -- Contracts, Biotechnology industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

Roche + Maxygen = $230 Million Interferons Roche acquired global commercialization rights to Maxygen's portfolio of interferon alpha and beta variants. The collaboration will focus on developing lead candidates for [...]

Published
2003

44. Micrologix and Hybridon to collaborate on antisense drug for HPV

Subjects
Company licensing agreement, Hybridon Inc. -- Licensing agreements, Micrologix Biotech Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Papillomavirus infections -- Care and treatment, Pharmaceutical industry -- Licensing agreements
Abstract

2002 OCT 31 - (NewsRx.com & NewsRx.net) -- Micrologix Biotech Inc., (MGIXF) and Hybridon, Inc., announced that they have entered into a collaboration and license agreement to develop an antisense [...]

Published
2002

45. Academic research is the engine of Europe's biotech industry

Author

Herrera, Stephan

Subjects
Company financing, Company licensing agreement, LION bioscience AG -- Licensing agreements -- Finance, Cellzome GmbH -- Finance -- Licensing agreements, European Molecular Biology Laboratory -- Licensing agreements, Biochemistry -- Research, Biotechnology industry -- Licensing agreements
Abstract

Nestled in the wooded hills surrounding the medieval German village of Heidelberg, the European Molecular Biology Laboratory (EMBL) is an apt metaphor for Europe's biotechnology industry. EMBL researchers produce groundbreaking […]

Published
2001

46. Technology-transfer activity

Subjects
Arbor Networks -- Licensing agreements, Mendel Biotechnology -- Licensing agreements, Synthon Chiragenics Corp. -- Licensing agreements, Universities and colleges -- Licensing agreements, Computer software industry -- Licensing agreements, Instructional materials industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Semiconductor industry -- Licensing agreements, Business, Business, regional, Michigan State University -- Licensing agreements
Abstract

Some companies that have recently licensed technology from Michigan universities: * Arbor Networks Inc., Ann Arbor Provides a computer network security service based on technology developed at the University of [...]

Published
2001

47. Aerotech to Produce New Mold Detector

Author

Siegel, James J.

Subjects
United States. Environmental Protection Agency -- Product information, Aerotech Laboratories Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Mold control -- Licensing agreements, Business, Construction and materials industries, Environmental services industry
Abstract

LATHAM, NY -- Aerotech Laboratories, Inc., has become the first firm to secure a manufacturing license for a mold-detection system developed by Environmental Protection Agency (EPA) scientists. The DNA-based system [...]

Published
2001

48. MARKETING NEWS

Subjects
Premium Brands -- Mergers, acquisitions and divestments, Valmont Industries Inc. -- Human resource management, Makhteshim-Agan of North America Inc. -- Licensing agreements, Aventis CropScience S.A. -- Licensing agreements, Archer Daniels Midland Co. -- Joint ventures, Kao Corp. -- Joint ventures, Olymel -- Mergers, acquisitions and divestments, DeLaval Inc. -- Joint ventures, Agricultural Building and Design Inc. -- Joint ventures, Hedlin Ag Enterprises Inc -- Mergers, acquisitions and divestments, GenomicFX -- Mergers, acquisitions and divestments, Genetic Solutions -- Mergers, acquisitions and divestments, Pesticides industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Food industry -- Joint ventures, Soap and cleaning agents industry -- Joint ventures, Toiletries industry -- Joint ventures, Oils and fats industry -- Joint ventures, Pork industry -- Mergers, acquisitions and divestments, Construction industry -- Joint ventures, Agricultural equipment and supplies industry -- Human resource management, Layoffs -- Nebraska, Employment services -- Mergers, acquisitions and divestments, Advertising, marketing and public relations, Agricultural industry, Business, Economics
Abstract

Makhteshim-Agan of North America, Inc., New York, has acquired from Aventis CropScience, Lyon, France, the U.S. rights to clofenzine, sold as Apollo Ovicide/Miticide, as part of a worldwide transfer of [...]

Published
2001

49. Gene Blues

Author

THOMPSON, NICHOLAS

Subjects
United States. Patent and Trademark Office -- Influence -- Analysis, Industrial policy -- Analysis -- United States, Biotechnology industry -- Licensing agreements, Genetic engineering -- Licensing agreements -- Analysis, Company licensing agreement, General interest, Political science
Abstract

Is the Patent Office prepared to deal with the genomic revolution? IT'S EASY TO TRIP ON A YELLOW-AND-GREEN binder on the 12th floor of the United States Patent and Trademark [...]

Published
2001

50. GENZYME GENERAL and the University of Michigan

Subjects
Genzyme Corp. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Business, Chemicals, plastics and rubber industries, University of Michigan -- Licensing agreements
Abstract

GENZYME GENERAL and the University of Michigan have entered into a license agreement for a class of smallmolecule compounds that may be useful in lysosomal disorder [...]

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results